TDOC Stock Recent News

Teladoc Health boasts substantial strengths and is positioned for enhanced performance, but according to new CEO Chuck Divita, there is work to do.

Teladoc's second-quarter financial results disappointed investors. The telemedicine company still has several things going its way.

Teladoc's new management has delivered a painful FQ2'24 earnings call, as observed in the BetterHelp impairment costs and withdrawn forward guidance. It is apparent that the telehealth company is facing growth issues and elevated marketing/advertising costs, with its near-term prospects likely to remain underwhelming. Readers must note the upcoming Livongo notes are likely to trigger further equity dilution, worsening the highly shorted stock's ongoing insider selling.

Teladoc Health (TDOC) expects revenue growth in the Integrated Care segment to be within low to mid-single-digit growth in 2024, on a year-over-year basis.

Teladoc Health, Inc. stock has plummeted >95% since its peak in early 2021, with the downtrend near constant. Losses are usually exacerbated by quarterly earnings, and Q2 earnings, announced yesterday, were no exception. Teladoc's new CEO withdrew all guidance for 2024, signaling potential challenges ahead, especially with the BetterHelp segment facing high customer acquisition costs and churn.

Teladoc Health's shares hit a record low on Thursday, as surging costs and declining revenue in its mental health services unit forced the virtual healthcare provider to withdraw its annual and long-term forecasts.

Teladoc reported a massive charge to earnings last night, and a huge earnings miss. The telemedicine company is still working through the consequences of its $18.5 billion purchase of Livongo four years ago.

U.S. stock futures were mixed this morning, with the Dow futures falling around 0.1% on Thursday.

Teladoc Health, Inc. (NYSE:TDOC ) Q2 2024 Earnings Conference Call July 31, 2024 4:30 PM ET Company Participants Chuck Divita - Chief Executive Officer Mala Murthy - Chief Financial Officer Michael Minchak - Head of Investor Relations Conference Call Participants Lisa Gill - J.P. Morgan Stephanie Davis - Barclays Jess Tassan - Piper Sandler Jailendra Singh - Truist Securities Richard Close - Cannacord Genuity Elizabeth Anderson - Evercore ISI Sarah James - Cantor Fitzgerald Sean Dodge - RBC Capital Markets Charles Rhyee - TD Cowen Michael Cherny - Leerink Partners Daniel Grosslight - Citi Operator Hello all, and welcome to Teladoc Health Second Quarter 2024 Earnings Call.

Although the revenue and EPS for Teladoc (TDOC) give a sense of how its business performed in the quarter ended June 2024, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.